SCHEMBL2818200

SCHEMBL2818200

CNc1nc2ccccc2n2cc(-c3ccc(OC)cc3OC)nc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 4/20 0.52
KDM4E B2RXH2 4/20 0.48
MAPT P10636 3/20 0.48
TLR9 Q9NR96 3/20 0.48
ADORA1 P30542 2/20 0.47
ADORA3 P0DMS8 1/20 0.46
TOP2A P11388 1/20 0.44
TP53 P04637 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ALDH1A1 P00352 1/20 0.43
POLB P06746 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
PKM P14618 1/20 0.43
TLR7 Q9NYK1 2/20 0.42
LCK P06239 1/20 0.41
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2818148 0.88 ADORA2A (0.67) ADORA2AKDM4EMAPTADORA1TOP2A
SCHEMBL2815374 0.86 ADORA2A (0.49) ADORA2AKDM4EMAPTTLR9ADORA1
SCHEMBL2815872 0.85 ADORA2A (0.55) ADORA2AKDM4EMAPTTLR9ADORA1
SCHEMBL2818141 0.84 ADORA2A (0.69) ADORA2ATLR9ADORA1ADORA3TLR7
SCHEMBL2815680 0.84 ADORA2A (0.54) ADORA2AKDM4EMAPTTLR9ADORA1
SCHEMBL2820462 0.83 ADORA2A (0.67) ADORA2AKDM4EMAPTADORA1TOP2A
SCHEMBL2816623 0.82 ADORA2A (0.69) ADORA2AKDM4EMAPTADORA1ADORA3
SCHEMBL2820066 0.81 ADORA2A (0.56) ADORA2AKDM4EMAPTADORA1TOP2A
SCHEMBL2818999 0.78 TOP2A (0.49) ADORA2AKDM4EMAPTADORA1TOP2A
SCHEMBL2814973 0.77 TP53 (0.48) ADORA2AKDM4EMAPTADORA3TOP2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2205602-B1 IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS UNIV MONTPELLIER (FR) 2018-09-26 EP disclosed
US-8378098-B2 Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers UNIVERSITE DE MONTPELLIER I (FR) 2013-02-19 US disclosed
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS IDH3A, NRAS, KRAS ADORA2A 1818/4885KDM4E 2878/4885MAPT 3888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.